Last reviewed · How we verify
CILGAVIMAB
At a glance
| Generic name | CILGAVIMAB |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Monoclonal antibody |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- COVID-19
Common side effects
Key clinical trials
- REAl LIfe" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (PHASE1)
- Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (PHASE2,PHASE3)
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (PHASE3)
- Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies with Early Access Authorization in Immunocompromised Patients. a Prospective Cohort.
- eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services
- Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CILGAVIMAB CI brief — competitive landscape report
- CILGAVIMAB updates RSS · CI watch RSS
- AstraZeneca portfolio CI